UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

WEE1 inhibition reverses trastuzumab resistance in HER2-positive cancers

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2021-09, Vol.24 (5), p.1003-1020

2021

Volltextzugriff (PDF)

Prospective evaluation of metabolic intratumoral heterogeneity in patients with advanced gastric cancer receiving palliative chemotherapy

Scientific reports, 2021-01, Vol.11 (1), p.296-296, Article 296

2021

Volltextzugriff (PDF)

ATR inhibition amplifies antitumor effects of olaparib in biliary tract cancer

Cancer letters, 2021-09, Vol.516, p.38-47

2021

Volltextzugriff (PDF)

HER2-targeted therapies beyond breast cancer — an update

Nature reviews. Clinical oncology, 2024-07

2024

Volltextzugriff (PDF)

Genetic and immune microenvironment characterization of HER2‐positive gastric cancer: Their association with response to trastuzumab‐based treatment

Cancer medicine (Malden, MA), 2023-05, Vol.12 (9), p.10371-10384

2023

Volltextzugriff (PDF)

Analysis of the role of tumor microenvironment on clinical outcomes of chemotherapy in patients with advanced gastric cancer using high plex digital spatial profiling

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.456-456

2023

Volltextzugriff (PDF)

Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study

The lancet. Gastroenterology & hepatology, 2022-06, Vol.7 (6), p.522-532

2022

Volltextzugriff (PDF)

A synthetic lethal strategy using PARP and ATM inhibition for overcoming trastuzumab resistance in HER2-positive cancers

Oncogene, 2022-08, Vol.41 (32), p.3939-3952

2022

Volltextzugriff (PDF)

Recent Progress in Immunotherapy for Gastric Cancer

Journal of gastric cancer, 2023, Vol.23 (1), p.207-223

2023

Volltextzugriff (PDF)

Recent Progress in Immunotherapy for Gastric Cancer

Journal of gastric cancer, 2023-01, Vol.23 (1), p.207-223

2023

Volltextzugriff (PDF)

Biomarker-oriented study of pembrolizumab in combination with chemotherapy in chemotherapy-naïve advanced pancreatic cancer: A phase 2 trial-in-progress

Journal of clinical oncology, 2022-02, Vol.40 (4_suppl), p.TPS639-TPS639

2022

Volltextzugriff (PDF)

Phase II study of sitravatinib in combination with tislelizumab in patients with advanced biliary tract cancer who have failed to at least 1 prior systemic treatment: Trial in progress

Journal of clinical oncology, 2022-02, Vol.40 (4_suppl), p.TPS490-TPS490

2022

Volltextzugriff (PDF)

A phase II biomarker-oriented study to evaluate paclitaxel, olaparib, and durvalumab combination in patients with advanced gastric cancer

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.404-404

2023

Volltextzugriff (PDF)

Abstract 1079: A synthetic lethal strategy using PARP and ATM inhibition for overcoming trastuzumab-resistance in HER2-positive cancers

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1079-1079

2021

Volltextzugriff (PDF)

Abstract 2073: Co-Targeting PARP and ATR in biliary tract cancer

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.2073-2073

2021

Volltextzugriff (PDF)

Health-related quality of life in patients treated with gemcitabine/cisplatin and durvalumab ± tremelimumab in chemotherapy-naïve advanced biliary tract cancer

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.4117-4117

2022

Volltextzugriff (PDF)

Clinical outcomes after incomplete cycles of R-CHOP for diffuse large B-cell lymphoma: 10 years’ real-world experience in a single institute

Annals of hematology, 2023-06, Vol.102 (6), p.1467-1476

2023

Volltextzugriff (PDF)

MED-TMA: A clinical decision support tool for differential diagnosis of TMA with enhanced accuracy using an ensemble method

Thrombosis research, 2020-09, Vol.193, p.154-159

2020

Volltextzugriff (PDF)

Randomized phase II study of nalicap (nal-IRI/capecitabine) compared to NAPOLI (nal-IRI/5-FU/LV) in gemcitabine-pretreated advanced pancreatic cancer: Trial-in-progress

Journal of clinical oncology, 2022-02, Vol.40 (4_suppl), p.TPS621-TPS621

2022

Volltextzugriff (PDF)

Co-mutation of ATM and ASXL1 and relationship to durable response of a novel PARP1/2 inhibitor, venadaparib, in patients with pancreatic cancer

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e15019-e15019

2023

Volltextzugriff (PDF)

The metabolic activity assessed by 18 F-FDG PET and its correlation with tumor immune status and prognosis in advanced biliary tract cancer patients treated with 1L GemCis plus durvalumab +/-tremelimumab

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.4092-4092

2023

Volltextzugriff (PDF)

CTX-009 (ABL001), a bispecific antibody targeting DLL4 and VEGF A, in combination with paclitaxel in patients with advanced biliary tract cancer (BTC): A phase 2 study

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.540-540

2023

Volltextzugriff (PDF)

Abstract 5334: Targeting the hippo transducer YAP overcomes trastuzumab-resistance in HER2-positive cancers

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.5334-5334

2022

Volltextzugriff (PDF)

Targeting Hypoxia Using Evofosfamide and Companion Hypoxia Imaging of FMISO-PET in Advanced Biliary Tract Cancer

Cancer Research and Treatment, 2021, 53(2), , pp.471-479

2021

Volltextzugriff (PDF)

Abstract 4496: JPI-547, a dual inhibitor of PARP/Tankyrase, shows promising antitumor activity against pancreatic cancers with homologous recombination repair deficiency or Wnt-addiction

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.4496-4496

2023

Volltextzugriff (PDF)

1 – 25 von 49

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(44)
Mit Volltextzugriff
(47)

Publikationsform

Artikel
(49)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(23)
Life Sciences & Biomedicine
(18)
Humans
(12)
Oncology
(10)
Chemistry
(6)
Animals
(5)
Female
(5)
Gastric Cancer
(5)
Medicine
(5)
Physical Sciences
(5)
Caenorhabditis Elegans
(4)
Chemotherapy
(4)
Medicine & Public Health
(4)
Original
(4)
Apoptosis
(3)
Biliary Tract Neoplasms - Drug Therapy
(3)
Biochemistry & Molecular Biology
(3)
Biomarkers
(3)
Cancer
(3)
Cell Line, Tumor
(3)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

WEE1 inhibition reverses trastuzumab resistance in HER2-positive cancers

Prospective evaluation of metabolic intratumoral heterogeneity in patients with advanced gastric cancer receiving palliative chemotherapy

ATR inhibition amplifies antitumor effects of olaparib in biliary tract cancer

HER2-targeted therapies beyond breast cancer — an update

Genetic and immune microenvironment characterization of HER2‐positive gastric cancer: Their association with response to trastuzumab‐based treatment

Analysis of the role of tumor microenvironment on clinical outcomes of chemotherapy in patients with advanced gastric cancer using high plex digital spatial profiling

Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study

A synthetic lethal strategy using PARP and ATM inhibition for overcoming trastuzumab resistance in HER2-positive cancers

Recent Progress in Immunotherapy for Gastric Cancer

Recent Progress in Immunotherapy for Gastric Cancer

Biomarker-oriented study of pembrolizumab in combination with chemotherapy in chemotherapy-naïve advanced pancreatic cancer: A phase 2 trial-in-progress

Phase II study of sitravatinib in combination with tislelizumab in patients with advanced biliary tract cancer who have failed to at least 1 prior systemic treatment: Trial in progress

A phase II biomarker-oriented study to evaluate paclitaxel, olaparib, and durvalumab combination in patients with advanced gastric cancer

Abstract 1079: A synthetic lethal strategy using PARP and ATM inhibition for overcoming trastuzumab-resistance in HER2-positive cancers

Abstract 2073: Co-Targeting PARP and ATR in biliary tract cancer

Health-related quality of life in patients treated with gemcitabine/cisplatin and durvalumab ± tremelimumab in chemotherapy-naïve advanced biliary tract cancer

Clinical outcomes after incomplete cycles of R-CHOP for diffuse large B-cell lymphoma: 10 years’ real-world experience in a single institute

MED-TMA: A clinical decision support tool for differential diagnosis of TMA with enhanced accuracy using an ensemble method

Randomized phase II study of nalicap (nal-IRI/capecitabine) compared to NAPOLI (nal-IRI/5-FU/LV) in gemcitabine-pretreated advanced pancreatic cancer: Trial-in-progress

Co-mutation of ATM and ASXL1 and relationship to durable response of a novel PARP1/2 inhibitor, venadaparib, in patients with pancreatic cancer

The metabolic activity assessed by 18 F-FDG PET and its correlation with tumor immune status and prognosis in advanced biliary tract cancer patients treated with 1L GemCis plus durvalumab +/-tremelimumab

CTX-009 (ABL001), a bispecific antibody targeting DLL4 and VEGF A, in combination with paclitaxel in patients with advanced biliary tract cancer (BTC): A phase 2 study

Abstract 5334: Targeting the hippo transducer YAP overcomes trastuzumab-resistance in HER2-positive cancers

Targeting Hypoxia Using Evofosfamide and Companion Hypoxia Imaging of FMISO-PET in Advanced Biliary Tract Cancer

Abstract 4496: JPI-547, a dual inhibitor of PARP/Tankyrase, shows promising antitumor activity against pancreatic cancers with homologous recombination repair deficiency or Wnt-addiction

Suchergebnisse filtern